25 results
Thumbnail

D1.422 - A service review of the complex COVID-19 vaccination service

Thumbnail

D1.425 - Familial Cold Autoinflammatory Syndrome Post COVID-19 Vaccine: A Case Report

Thumbnail

D1.423 - Listening to Urticaria Patients Through Social Media: Analyzing the Impact of the COVID-19 Pandemic

Thumbnail

D1.424 - Clinical-epidemiological profile of patients with Post-Covid syndrome followed at a medical school outpatient clinic

Thumbnail

D1.426 - Cellular immunity profile in patients with urolithiasis in the presence of post-Covid syndrome

Thumbnail

D2.342 - Changes of MMP-9 and MMP-12 in response of acute viral infection in virtual model of macrophages

Thumbnail

D2.343 - Use of IDDA 2.1 score in Common Variable Immunodeficiency (CVID): a single center experience

Thumbnail

D2.344 - Unraveling the Mysteries of Chronic Granulomatous Disease: A Case of detected Protein Deficiency Amidst Negative Genetic Screening

Thumbnail

D2.345 - Conformations of HVEM engaged in its Trans and Cis interactions are caused by two kinds of post-translational folding

Thumbnail

D2.346 - Assessment of the safety of allogenic natural killer cells in the treatment of metastatic colon cancer

Thumbnail

D2.347 - Allergen-Specific T Cells to House Dust Mite are absent on the circulation of local allergic rhinitis patients

Thumbnail

D2.348 - Clinical Course of Hereditary Angioedema Patients Transitioning off Androgens

Thumbnail

D2.349 - Hereditary Angioedema in Bulgaria: an update on patient characteristics and treatment modalities

Thumbnail

D2.350 - CVID: the crossroad between immune dysregulation, autoimmunity and cancer

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes